Drug Database
FI

filgrastim (long-acting)

✓ Approved

Win Medica · CSF3R · Recombinant Proteins

What is filgrastim (long-acting)?

filgrastim (long-acting) is a recombinant proteins developed by Win Medica. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyWin Medica
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Win Medica

Mechanism of Action

Molecular Targets

filgrastim (long-acting) acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

filgrastim (long-acting) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersBone marrow disorder✓ Approved

Related Research Articles

PubMedInternational journal of nanomedicine2026-09-20

Injectable Hyaluronic Acid-Functionalized Nanocomposite Hydrogel for Targeted Rheumatoid Arthritis Therapy via Concurrent ROS Attenuation and Macrophage Repolarization.

Fan Ziyan Z, Wang Runkong R, Zhang Qiang Q, Wu Mingquan M et al.

The clinical treatment of rheumatoid arthritis (RA), a chronic systematic autoimmune disease marked by persistent synovial inflammation and irreversible joint damage, remains substantially challenging due to the limitations of current therapies including insufficient targeting, short intra-articular retention and off-target adverse effects. Therefore, developing an injectable, long-acting and targeted therapeutic hydrogel platform is urgently needed for precise and efficient RA treatment. We developed an injectable long-acting nanocomposite hydrogel platform (HA-BR nano-GEL@CLT) which integrated hyaluronic acid (HA)-polyethylene glycol (PEG) co-polymeric matrix encapsulating HA-bilirubin nanoparticles (HA-BR NPs) and celastrol (CLT). The hydrogel was characterized and its in vitro biocompatibility, antioxidant, anti-inflammatory, and macrophage polarization effects were evaluated. In vivo therapeutic efficacy and biosafety were assessed in adjuvant-induced arthritis (AIA) rats. The average particle size of fabricated HA-BR NPs@CLT was 118.5 nm and the gel formulation underwent a rapid sol‑to‑gel phase transition within 200 seconds. HA-BR nano-GEL@CLT exhibited strong biomimetic lubrication, anti-inflammatory and antioxidant capacities, and could effectively modulate the polarization of macrophages in vitro, with the result that the M1/M2 ratio in HA-BR nano-GEL@CLT group was only 0.19-fold that of model group. The hydrogel also provided long-term intra-articular retention up to 21 days in AIA rats. It significantly alleviated paw swelling, inhibited bone erosion, modulated the levels of inflammatory cytokines, whereas the expressions of IL-6 and TNF-α were reduced by 27% and 43%, and the expression of IL-10 was increased by 47%, compared to HA GEL@CLT group. Besides, HA-BR nano-GEL@CLT also alleviated oxidative damage, regulated macrophage polarization and reduced systemic toxicity of CLT in vivo. This injectable nanocomposite hydrogel platform offers an efficient and promising approach to suppress RA progression via ROS attenuation and macrophage repolarization.

PMID 42763682
Read full article →
PubMedJournal of arrhythmia2026-09-20

Permanent Cardiac Pacing in Children: A 30-Year Follow-Up Retrospective Study in a Single Pediatric Asian Center.

Chan Jiahui Charmaine JC, Zhang Dyan Zhewei DZ, Xuan Koh Zhi KZ, Sundararaghavan Sreekanthan S et al.

Permanent cardiac pacing in children is commonly indicated in high-grade atrioventricular block. These patients require long-term ventricular pacing (Vp), multiple device changes, and lead revisions. To describe a single pediatric center's 30-year experience with permanent pacemaker implantation, focusing on long-term device-associated complications (DACs) and pacing-induced cardiomyopathy (PIC). We conducted a retrospective observational study at KK Women's and Children's Hospital, Singapore. Patients with permanent pacemakers followed between January 1, 1994 and December 31, 2024 were included. Primary outcomes were DAC and PIC. Fifty-three patients underwent 113 pacemaker lead implantations; 51 (96.2%) had epicardial systems. Median follow-up was 12 years (interquartile range [IQR] 9-19 years). Median age at first pacemaker implantation was 16 months (IQR 2 months to 7.7 years). Congenital complete heart block was the most common indication (26 [49%]), followed by postoperative complete heart block (17 [32%]). Freedom from lead-associated complications was 85% and 83% at 5 and 10 years, respectively. Eight (15%) patients developed PIC. All patients with PIC had concomitant congenital heart disease (CHD) (8/8). CHD was present in 28.9% (13/45) of patients without PIC. Recovery of ventricular function occurred in two patients following pacing modification, but not in those managed with medical therapy alone. In this pediatric cohort with predominantly epicardial pacing systems, long-term DAC rates were acceptable. PIC occurred primarily in patients with CHD. These findings support careful pacing strategy selection and long-term surveillance in children requiring permanent pacing.

PMID 42763570
Read full article →
PubMedDrug development research2026-09-20

Statins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gap.

Zhou Xu X, Chen Yizhang Y, Hua Hanxiao H, Shen Bo B et al.

Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and reduce flux through the mevalonate pathway, which supplies both cholesterol and the non-sterol isoprenoids required for prenylation of small GTPases. Because this pathway is frequently activated in cancer, statins have become one of the most intensively studied candidates for oncological drug repurposing. Preclinical work indicates that statins can lower the threshold for apoptosis, modulate autophagy in either a pro-death or a cytoprotective direction, induce pyroptosis, and sensitize cells to ferroptosis, while also acting on CD8+ T cells, macrophages, dendritic cells, and cancer-associated fibroblasts within the tumor microenvironment. Clinical evidence, however, remains discordant with the strength of these mechanistic claims: favorable observational associations are susceptible to immortal-time bias, healthy-user bias, and confounding by indication, and randomized trials have been largely neutral for tumor-directed endpoints. This narrative review appraises the mechanistic, preclinical, and clinical literature using an explicit five-tier evidence hierarchy, and treats two constraints as analytical tools rather than closing caveats: the pharmacological heterogeneity of individual statins, and the one-to-two order-of-magnitude gap between concentrations used in cancer-cell experiments and free drug concentrations achievable in patients. We conclude that statins are biologically plausible but clinically unproven anticancer agents whose evaluation should proceed through biomarker-selected, pharmacodynamically validated combination trials rather than unselected add-on designs.

PMID 42763787
Read full article →
PubMedJournal of oncology2026-09-20

RETRACTION: Long Noncoding RNA NR2F1-AS1 Enhances the Migration and Invasion of Hepatocellular Carcinoma via Modulating miR-642a/DEK Pathway.

Oncology Journal Of JO

[This retracts the article DOI: 10.1155/2021/6868514.].

PMID 42763456
Read full article →
PubMedSolar physics2026-09-20

Physics-Constrained Reconstructions of Sunspot Number from Millennial-Scale Annual Heliospheric Modulation Potential.

Saha Chitradeep C, Owens Mathew M, Lockwood Mike M, Barnard Luke L et al.

Long-term solar magnetic variability governs the space climate conditions. These variations also modulate the galactic cosmic ray influx reaching Earth and subsequently regulate the production of cosmogenic isotopes in Earth's atmosphere. By harnessing the multi-millennial records of the abundances of these radio-isotopes stored in natural terrestrial reservoirs, such as tree wood and ice sheets, it is possible to reconstruct past solar magnetic activity predating the telescopic era. However, existing regression-based reconstruction methods using isotope data from time series extracted from the reservoirs are often applied to conditions outside the valid parameter range. This can result in a number of problems, including negative sunspot numbers during low solar activity phases, which correspond to statistically permissible extrapolation artefacts but have no physical meaning. To address this, we developed a Monte-Carlo inversion framework consisting of a sequence of physics-based semi-empirical forward models, supplemented by an Approximate Bayesian Computation-based posterior selection, to infer the most plausible temporal evolution of solar magnetic parameters. Our approach produces physically consistent, uncertainty-quantified reconstructions of annually resolved parameters, including sunspot numbers. We apply the method to two modulation potential datasets, namely geomagnetic record from 1845 - 2020, and an annual 14C estimate over the period 971 - 1932. Our new reconstruction method is designed to yield strictly non-negative sunspot numbers and shows close agreement with direct observations within uncertainty during the telescopic era. These results offer valuable insights into long-term solar variability and provide improved constraints for long-term solar dynamo modelling. The annual-scale reconstructions are also directly usable for solar irradiance estimation, terrestrial climate modelling, and studies of long-term Sun-Earth coupling. The online version contains supplementary material available at https://doi.org/10.1007/s11207-026-02731-0.

PMID 42763450
Read full article →
PubMedEsophagus : official journal of the Japan Esophageal Society2026-09-20

Long-term nutritional outcomes after esophagectomy following induction chemotherapy versus chemoradiotherapy for T4b esophageal cancer.

Sugimura Keijiro K, Tanaka Koji K, Sugase Takahito T, Momose Kota K et al.

The long-term impact of preoperative treatment on nutritional recovery after esophagectomy remains unclear. Although neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) followed by surgery are established strategies for advanced esophageal cancer, their differential effects on postoperative weight loss have not been well characterized. This study aimed to compare long-term nutritional outcomes between esophagectomy after induction chemotherapy and after induction chemoradiotherapy in patients with T4b esophageal cancer. We retrospectively analyzed 86 patients with T4b esophageal cancer who underwent conversion surgery after induction treatment at six institutions between 2009 and 2021. Patients were categorized into a chemotherapy group (CT group, n = 51) and a chemoradiotherapy group (CRT group, n = 35). Longitudinal changes in body weight, lymphocyte counts, serum albumin levels, and prognostic nutritional index (PNI) were evaluated up to 24 months postoperatively. Postoperative weight loss was significantly greater in the CRT group than in the CT group, particularly at 9 and 12 months postoperatively (-13.4% vs. -9.6%, P = 0.011; -13.8% vs. -9.3%, P = 0.022). Weight loss persisted until 12 months after esophagectomy in the CRT group, whereas gradual recovery was observed after 6 months in the CT group. Lymphocyte counts were consistently lower in the CRT group from preoperation through 24 months postoperatively (all P < 0.05). Serum albumin levels did not differ significantly between groups. One year after surgery, deterioration in PNI was significantly greater in the CRT group (P < 0.001). Esophagectomy following induction chemoradiotherapy was associated with greater long-term weight loss and impaired nutritional recovery compared with surgery following chemotherapy alone. These findings highlight the need for intensified nutritional surveillance and intervention in patients treated with preoperative CRT.

PMID 42763385
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about filgrastim (long-acting)